- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc stock price live, this page displays NASDAQ TBPH stock exchange data. View the TBPH premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Theravance Biopharma Inc real time stock price chart below.
What Is the Theravance Biopharma Inc Stock Price Today?
The Theravance Biopharma Inc stock price today is 13.80.
What Is the Stock Symbol for Theravance Biopharma Inc?
The stock symbol for Theravance Biopharma Inc is ""TBPH.""
What Stock Exchange Does Theravance Biopharma Inc Trade On?
Theravance Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Theravance Biopharma Inc a Good Stock to Buy?
Determining whether Theravance Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TBPH quote. (ISIN: KYG8807B1068)
What Is the Theravance Biopharma Inc Stock Price Today?
The Theravance Biopharma Inc stock price today is 13.80.
What Is the Stock Symbol for Theravance Biopharma Inc?
The stock symbol for Theravance Biopharma Inc is ""TBPH.""
What Stock Exchange Does Theravance Biopharma Inc Trade On?
Theravance Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Theravance Biopharma Inc a Good Stock to Buy?
Determining whether Theravance Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TBPH quote. (ISIN: KYG8807B1068)
Fair Value
An estimate of a Theravance Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.67
13.83
52 wk Range
7.88
14.30
TBPH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TBPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Theravance Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.6713.83
52 wk Range
7.8814.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TBPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Theravance Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
18.40
Upside
+33.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Theravance Biopharma Inc Company Profile
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of $1.08 beat forecast by 61.19%, revenue of $26.2M exceeded expectations by 64.57%, stock rose 4.56% after hours
- YUPELRI net sales grew 22% year-over-year, contributing to strong revenue growth; company ended quarter with $340M cash and no debt
- Company reaffirmed 2025 guidance, expecting improved non-GAAP losses and reduced cash burn in H2; analysts project profitability this year
- Awaiting top-line data from Cypress Phase 3 study in ~6 months; potential milestone payments from Trelegy and YUPELRI could boost performance
- Management addressed pricing strategy for ampreloxetine (~$380,000/year) and confirmed stable SG&A spending until Cypress data readout
Last Updated: 12/08/2025, 22:54
Read Full TranscriptCompare TBPH to Peers and Sector
Metrics to compare | TBPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTBPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 53.3x | −1.5x | −0.6x | |
PEG Ratio | 0.42 | 0.37 | 0.00 | |
Price/Book | 3.1x | 2.8x | 2.6x | |
Price / LTM Sales | 9.0x | 1.8x | 3.3x | |
Upside (Analyst Target) | 8.7% | 112.5% | 38.7% | |
Fair Value Upside | Unlock | 14.0% | 5.1% | Unlock |
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 18.40
(+33.33% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
1.08 / 0.67
Revenue / Forecast
26.20M / 15.92M
People Also Watch
FAQ
What Stock Exchange Does Theravance Biopharma Trade On?
Theravance Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Theravance Biopharma?
The stock symbol for Theravance Biopharma is "TBPH."
What Is the Theravance Biopharma Market Cap?
As of today, Theravance Biopharma market cap is 694.99M.
What Is Theravance Biopharma's Earnings Per Share (TTM)?
The Theravance Biopharma EPS (TTM) is 0.26.
When Is the Next Theravance Biopharma Earnings Date?
Theravance Biopharma will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is TBPH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Theravance Biopharma Stock Split?
Theravance Biopharma has split 0 times.
How Many Employees Does Theravance Biopharma Have?
Theravance Biopharma has 97 employees.
What is the current trading status of Theravance Biopharma (TBPH)?
As of 28 Aug 2025, Theravance Biopharma (TBPH) is trading at a price of 13.80, with a previous close of 13.80. The stock has fluctuated within a day range of 13.67 to 13.83, while its 52-week range spans from 7.88 to 14.30.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.